Menu Close

Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic Acid (TOPaZ) Trial

  • Posted on Feb 13, 2018

If you have a diagnosis of Osteogenesis Imperfecta (OI) and are aged 18 years or over, you may be eligible for the Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic Acid (TOPaZ) Trial across the UK and Ireland. The study aims to determine whether a two-year spell with a treatment called Teriparatide (TPTD) followed by treatment with another drug called Zoledronic Acid (ZA) reduces the risk of broken bones occurring in people with OI as compared to standard care.

If you would like to find out more information, please contact the research team:

Holly Ennis, TOPaZ Trial office: 0131 537 2573 or topaz.trial@ed.ac.uk

Alternatively, please take a look at their website where you will also find information on their participating sites or see the TOPaZ Trial information leaflet.

TOPaZ is a non-commercial trial sponsored by a partnership of the University of Edinburgh and NHS Lothian called ACCORD and funded by the UK National Institute for Health Research (NIHR).

Get involved Categories